NanoAlvand is relevant for investors assessing Iran's advanced pharmaceutical manufacturing, oncology and specialty-drug demand, high-potency production capability, import substitution, technology gaps, and export potential in complex generics. It can support analysis of how local firms move from basic generics toward higher-value medicines under regulatory and sanctions constraints. Due diligence should verify ownership, GMP status, product registrations, current manufacturing sites, active pharmaceutical ingredient sourcing, export registrations, pharmacovigilance systems, intellectual-property exposure, quality-control capacity, and international market access.